NSE · Healthcare · Biotechnology
EPS came in at 0.95 against a street estimate of 1.09 — a miss of 12.8%.
with an average price target of ₹446.89.
CONFIDENT Biocon delivered 10% YoY revenue growth with biosimilars up 16% and generics surging 21%. New launches (Aflibercept, Denosumab) and Malaysia insulin facility approval expected to drive second-half acceleration. Profitability focus over market share with debt declining. Q1 FY27 North America remains largest and most strategic; Europe provides stable margins; emerging markets expanding access and tender wins. Analysts pressed on base business growth ex-Liraglutide (management: single-digit + new launches, no abnormal competition). Aflibercept market share concern addressed (myth busted on ophthalmology adoption). Biosimilars margin expansion debated (normalized 24–25% expected to improve via new launches). 2026-08-06…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call BIOCON LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Operating revenue grew 10% year-on-year to INR 4,353 crores (group level) • EBITDA reac | 2026-08-11 |
| Investor presentation · Q1 FY27 BIOCON LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹4,336 Cr in Q1 FY27, up 10% year-on-year (YoY) from ₹3,942 Cr | 2026-08-06 |
| Quarterly results · Q1 FY27 BIOCON LIMITED - Q1 FY2026-27 FINANCIAL SUMMARY HEADLINE NUMBERS • Standalone Revenue from Operations (Q1 FY27): Rs. 6,245 million (vs Rs. 5,371 mil | 2026-08-05 |
| Annual report FY2026 BIOCON LIMITED – SHAREHOLDER SUMMARY FY 2025-26 HEADLINE NUMBERS • Total Income: ₹172,695 million (USD 1.96 billion), growth 14% • EBITDA: ₹37,978 m | 2026-07-15 |
| Investor presentation · Q4 FY26 BIOCON LIMITED INVESTOR PRESENTATION SUMMARY (JUNE 2026) HEADLINE NUMBERS • Revenue FY26: $1,924 million (₹16,927 crores), with biosimilars at 60%, | 2026-06-01 |
| Q4 FY26 earnings call BIOCON LIMITED Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Operating revenue grew 10% year-on-year (excluding one-time generic lenalidomide | 2026-05-14 |
| Investor presentation | 2026-05-08 |
| Quarterly results · Q4 FY26 BIOCON LIMITED – BOARD MEETING OUTCOME (MAY 07, 2026) HEADLINE NUMBERS • Final dividend recommended at 10% i.e. Re. 0.50 per equity share (face valu | 2026-05-07 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.50 / share ex-date Jul 3, 2026 | 2026-07-03 |
| Announcement | Date |
|---|---|
| Secures 10-year supply contract for Pertuzumab in Brazil Biocon Limited announced a 10-year supply contract for Pertuzumab (a HER2-positive breast cancer treatment) in Brazil through a partnership with local companies Bahiafarma and Bionovis under | 2026-09-08 |
| Acquisition announced by the company Biocon Limited has informed the Exchange about Acquisition | 2026-06-29 |
| Acquisition announced Biocon Limited has informed the Exchange about Acquisition | 2026-06-10 |
| Company acquires another business or forms strategic partnership Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026-Acquisition | 2026-05-07 |
| Acquisition announced by company Biocon Limited has informed the Exchange about Acquisition | 2026-03-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biocon Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.